Contact information
Katherine England
Postdoctoral Researcher
Katherine holds a D.Phil. in Organic Chemistry from the University of Oxford for her work on inhibitors of epigenetic proteins. She has worked in drug discovery across a variety of disease areas and drug classes in industry and academia and has been a member of the medicinal chemistry team at the Alzheimer’s Research UK Oxford Drug Discovery Institute (ODDI) since 2015.
Katherine is a team leader in the medicinal chemistry group contributing to a range of projects in the ODDI portfolio.
Recent publications
-
Structural Premise of Selective Deubiquitinase USP30 Inhibition by Small-Molecule Benzosulfonamides
Journal article
O'Brien DP. et al, (2023), Molecular & Cellular Proteomics, 22, 100609 - 100609
-
Structural Premise of Selective Deubiquitinase USP30 Inhibition by Small-Molecule Benzosulfonamides
Preprint
O’Brien DP. et al, (2022)
-
USP30 sets a trigger threshold for PINK1–PARKIN amplification of mitochondrial ubiquitylation
Journal article
Rusilowicz-Jones EV. et al, (2020), Life Science Alliance, 3, e202000768 - e202000768
-
C8-substituted pyrido[3,4-d]pyrimidin-4(3H)-ones: Studies towards the identification of potent, cell penetrant Jumonji C domain containing histone lysine demethylase 4 subfamily (KDM4) inhibitors, compound profiling in cell-based target engagement assays.
Journal article
Le Bihan Y-V. et al, (2019), European journal of medicinal chemistry, 177, 316 - 337
-
Potent and Selective KDM5 Inhibitor Stops Cellular Demethylation of H3K4me3 at Transcription Start Sites and Proliferation of MM1S Myeloma Cells
Journal article
Tumber A. et al, (2017), Cell Chemical Biology, 24, 371 - 380